Department of Neurology, Monash Medical Centre, Clayton, Australia.
Stroke and Aging Research Group, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia.
PLoS One. 2023 May 1;18(5):e0281617. doi: 10.1371/journal.pone.0281617. eCollection 2023.
Post-stroke pneumonia is a frequent complication of stroke and is associated with high mortality. Investigators have described its associations with beta-blocker. However, there has been no evaluation of the role of recombinant tissue plasminogen activator (RTPA). We postulate that RTPA may modify the effect of stroke on pneumonia by reducing stroke disability. We explore this using data from neuroprotection trials in Virtual International Stroke Trials Archive (VISTA)-Acute.
We evaluated the impact of RTPA and other medications in random forest model. Random forest is a type of supervised ensemble tree-based machine learning method. We used the standard approach for performing random forest and partitioned the data into training (70%) and validation (30%) sets. This action enabled to the model developed on training data to be evaluated in the validation data. We borrowed idea from Coalition Game Theory on fair distribution of marginal profit (Shapley value) to determine proportional contribution of a covariate to the model. Consistent with other analysis using the VISTA-Acute data, the diagnosis of post-stroke pneumonia was based on reports of serious adverse events.
The overall frequency of pneumonia was 10.9% (614/5652). It was present in 11.5% of the RTPA (270/2358) and 10.4% (344/3295) of the no RTPA groups. There was significant (p<0.05) imbalance in covariates (age, baseline National Institutes of Health Stroke Scale (NIHSS), diabetes, and sex). The AUC for training data was 0.70 (95% CI 0.65-0.76), validation data was 0.67 (95% CI 0.62-0.73). The Shapley value shows that baseline NIHSS (≥10) and age (≥80) made the largest contribution to the model of pneumonia while absence of benzodiazepine may protect against pneumonia. RTPA and beta-blocker had very low effect on frequency of pneumonia.
In this cohort pneumonia was strongly associated with stroke severity and age whereas RTPA had a much lower effect. An intriguing finding is a possible association between benzodiazepine and pneumonia but this requires further evaluation.
卒中后肺炎是中风的常见并发症,与高死亡率相关。研究人员描述了其与β受体阻滞剂的关系。但是,尚未评估重组组织型纤溶酶原激活剂(rTPA)的作用。我们推测 rTPA 通过降低中风残疾程度可能改变中风对肺炎的影响。我们使用虚拟国际中风试验档案(VISTA)-急性神经保护试验的数据对此进行了探讨。
我们在随机森林模型中评估了 rTPA 和其他药物的影响。随机森林是一种监督集合树基机器学习方法。我们使用了执行随机森林的标准方法,并将数据分为训练(70%)和验证(30%)集。这使得在训练数据上开发的模型能够在验证数据中进行评估。我们借鉴了联盟博弈论中关于边际利润公平分配(Shapley 值)的思想,以确定协变量对模型的贡献比例。与使用 VISTA-Acute 数据的其他分析一致,中风后肺炎的诊断基于严重不良事件报告。
肺炎的总体发生率为 10.9%(614/5652)。rTPA 组(270/2358)和非 rTPA 组(344/3295)的发生率分别为 11.5%和 10.4%。协变量(年龄、基线国立卫生研究院中风量表(NIHSS)、糖尿病和性别)存在显著(p<0.05)不平衡。训练数据的 AUC 为 0.70(95%CI 0.65-0.76),验证数据的 AUC 为 0.67(95%CI 0.62-0.73)。Shapley 值表明,基线 NIHSS(≥10)和年龄(≥80)对肺炎模型的贡献最大,而没有使用苯二氮䓬类药物可能会预防肺炎。rTPA 和β受体阻滞剂对肺炎的发生率影响很小。
在本队列中,肺炎与中风严重程度和年龄密切相关,而 rTPA 的影响较小。一个有趣的发现是苯二氮䓬类药物与肺炎之间可能存在关联,但这需要进一步评估。